Fig. 7: Kaplan–Meier estimates of time to event by serial ctDNA dynamics relative to baseline. | npj Precision Oncology

Fig. 7: Kaplan–Meier estimates of time to event by serial ctDNA dynamics relative to baseline.

From: Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab

Fig. 7: Kaplan–Meier estimates of time to event by serial ctDNA dynamics relative to baseline.The alternative text for this image may have been generated using AI.

a PFS stratified by post-baseline ctDNA scores relative to baseline prior to progression, death, or the end of FU, whichever occurred first (n = 63). b OS stratified by post-baseline ctDNA scores relative to baseline (n = 63). Serial ctDNA status was categorized as either all blood draws show a decrease after the baseline timepoint (blue) or any blood draw shows an increase after the baseline timepoint (pink). The statistical significance of the difference between the two curves was assessed using a two-sided log-rank test. HRs for PFS and OS were estimated using Cox proportional hazards models. HR hazard ratio, OS overall survival, PFS progression-free survival, FU follow-up.

Back to article page